Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Rajan et al.
Journal for ImmunoTherapy of Cancer
October 2019
Authors and Affiliates
Rajan A1, Heery CR2, Thomas A3, Mammen AL4, Perry S3, O'Sullivan Coyne G5, Guha U3, Berman A3, Szabo E3,6, Madan RA5, Ballester LY7, Pittaluga S7, Donahue RN2, Tsai YT2, Lepone LM2, Chin K8, Ginty F9, Sood A9, Hewitt SM7, Schlom J2, Hassan R3, Gulley JL10;
1
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10-CRC, Room 4-5330, 10 Center Drive, Bethesda, MD, 20892, USA. rajana@mail.nih.gov.
2
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
3
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10-CRC, Room 4-5330, 10 Center Drive, Bethesda, MD, 20892, USA.
4
Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
5
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., 13N240, Bethesda, MD, 20892, USA.
6
Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
7
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
8
EMD Serono, Billerica, MA, USA.
9
GE Global Research Center, Niskayuna, NY, USA.
10
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., 13N240, Bethesda, MD, 20892, USA. gulleyj@mail.nih.gov.